Pulmonary Hypertension Trial, Recruiting NCT06549452 Sponsor: Vanderbilt University Medical Center Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Pulmonary Hypertension Trial, Recruiting

NCT06549452
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between the ages of 10 and 21 years old
  • People who have been diagnosed with a specific type of pulmonary hypertension classified as either WHO Group 1 (PAH) or WHO Group 4 (CTEPH)
  • People whose condition falls within WHO functional class I, II, or III (meaning symptoms range from none to moderate limitations on physical activity)
  • People who have been on a stable treatment plan for their pulmonary hypertension for at least three months before joining, with only one diuretic (fluid-reducing medication) dose adjustment allowed in that time — adjustments to IV prostacyclin for managing side effects are also permitted

Who may not be able to join:

  • People whose mobility is limited by being wheelchair-bound, bed-bound, reliant on a cane or walker, or who have another condition that significantly limits their physical activity (such as activity-limiting chest pain or joint disease)
  • People who are pregnant
  • People whose pulmonary hypertension has a cause other than idiopathic (unknown cause), heritable (genetic), or associated types (confirm with trial site)
  • People with the most severe level of heart failure, classified as WHO functional class IV
  • People who have needed more than two diuretic medication adjustments in the three months before joining
  • People whose preferred form of physical activity cannot be tracked by a standard activity tracker — this includes swimming, yoga, ice skating, stair climbing machines, bicycling, or rollerblading
  • People who are currently participating in another clinical research study involving an investigational treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Eric Austin, MD, Vanderbilt University Medical Center

Phone: (434) 851-3306

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 December 2024
Est. completion
1 November 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in average daily step count from baseline to 12 weeks

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov